What have we learnt thus far from mice with disrupted P-glycoprotein genes?

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 985-990

  Borst, P ^a   Schinkel, A H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CARRIER PROTEIN; CYCLOSPORIN A; DEXAMETHASONE; DIGOXIN; GENE PRODUCT; GLYCOPROTEIN P; IVERMECTIN; MORPHINE; PHOSPHATIDYLCHOLINE; VERAPAMIL; VINBLASTINE;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER CELL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG TRANSPORT; HUMAN; HUMAN CELL; MOUSE; MULTIDRUG RESISTANCE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; DRUG RESISTANCE, NEOPLASM; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN;

EID: 0029945113     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00063-9     Document Type: Article

References (39)

1. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993, 53, 747-754.
2. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 1995, 9, 363-382.
3. Borst P, Schinkel AH. Mice with disrupted P-glycoprotein genes. In Gupta S, Tsuruo T, eds. Multidrug Resistance in Cancer Cells. New York/London, John Wiley & Sons Ltd, 1996, in press.
4. Borst P, Schinkel AH, Smit JJM, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993, 60, 289-299.
5. Lum BL, Gosland MP. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematology/Oncology Clinics of North America 1995, 9, 319-336.
6. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepülveda FV, Higgins CF. Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 1995, 14, 68-75.
7. Coon JS, Wang Y, Bines S, Markham PM, Chong AS-F, Gebel HM. Multidrug resistance activity in human lymphocytes. Hum Immunol 1991, 32, 134-140.
8. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83, 2451-2458.
9. Nooter K, Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res 1994, 18, 233-243.
10. Chong AS-F, Markham PN, Gebel HM, Bines SD, Coon JS. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells. Cancer Immunol Immunother 1993, 36, 133-139.
11. Zhang L, Sachs CW, Fu H-W, Fine RL, Casey PJ. Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. J Biol Chem 1995, 270, 22859-22865.
12. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, in press.
13. Field FJ, Born E, Chen H, Murthy S, Mathur SN. Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in CaCo-2 cells: possible role of P-glycoprotein. J Lipid Res 1995, 36, 1533-1543.
14. Schinkel AH, Smit JJM, Van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
15. Schinkel AH, Mol CAAM, Wagenaar E, Van Deemter L, Smit JJM, Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 1995, 31A, 1295-1298.
16. Schinkel AH, Wagenaar E, Van Deemter L, Mol CAAM, Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995, 96, 1698-1705.
17. Van Tellingen O, Beijnen JH, Nooijen WJ, Bult A. Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography. Cancer Chemother Pharmacol 1993, 32, 286-292.
18. Van Tellingen O, Beijnen JH, Nooijen WJ, Bult A. Plasma pharmacokinetics of vinblastine and the investigational vinca alkaloid n-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography. Cancer Res 1993, 53, 2061-2065.
19. Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989, 9, 1346-1350.
20. Teeter LD, Becker FF, Chisari FV, Li D, Kuo MT. Over-expression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 1990, 10, 5728-5735.
21. van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 1987, 6, 3325-3331.
22. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989, 9, 3808-3820.
23. Smit JJM, Schinkel AH, Mol CAAM, et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994, 71, 638-649.
24. Buschman E, Arceci RJ, Croop JM, et al. Mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies. J Biol Chem 1992, 267, 18093-18099.
25. Smit JJM, Schinkel AH, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75, 451-462.
26. Ruetz S, Gros P. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994, 77, 1071-1083.
27. Smith AJ, Timmermans-Hereijgers JLPM, Roelofsen B, et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 1994, 354, 263-266.
28. Oude Elferink RPJ, Ottenhoff R, Van Wijland M, Smit JJM, Schinkel AH, Groen AK. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 1995, 95, 31-38.
29. Ruetz S, Gros P. Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. J Biol Chem 1995, 270, 25388-25395.
30. Buschman E, Gros P. Functional analysis of chimeric genes obtained by exchanging homologous domains of the mouse mdr1 and mdr2 genes. Mol Cell Biol 1991, 11, 595-603.
31. Schinkel AH, Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein specific monoclonal antibodies. Cancer Res 1991, 51, 2628-2635.
32. Buschman E, Gros P. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein. Cancer Res 1994, 54, 4892-4898.
33. Nooter K, Sonneveld P, Janssen A, et al. Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer 1990, 45, 626-631.
34. Herweijer H, Sonneveld P, Baas F, Nooter K. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990, 82, 1133-1140.
35. Böhme M, Jedlitschky G, Leier I, Büchler M, Keppler D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv Enz Reg 1994, 34, 371-380.
36. Childs S, Ych RL, Georges E, Ling V. Identification of a sister gene to P-glycoprotein. Cancer Res 1995, 55, 2029-2034.
37. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993, 11, 1629-1635.
38. McLeod HL. Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? Eur J Cancer 1994, 30A, 2039-2041.
39. Taylor HG, Pacqué M, Muñoz B, Greene BM. Impact of mass treatment of onchocerciasis on the transmission of infection. Science 1990, 250, 116-118.